JP2012090630A5 - - Google Patents

Download PDF

Info

Publication number
JP2012090630A5
JP2012090630A5 JP2011235922A JP2011235922A JP2012090630A5 JP 2012090630 A5 JP2012090630 A5 JP 2012090630A5 JP 2011235922 A JP2011235922 A JP 2011235922A JP 2011235922 A JP2011235922 A JP 2011235922A JP 2012090630 A5 JP2012090630 A5 JP 2012090630A5
Authority
JP
Japan
Prior art keywords
sulfatase
composition
fge
cell
arylsulfatase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011235922A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012090630A (ja
JP5527854B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2012090630A publication Critical patent/JP2012090630A/ja
Publication of JP2012090630A5 publication Critical patent/JP2012090630A5/ja
Application granted granted Critical
Publication of JP5527854B2 publication Critical patent/JP5527854B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2011235922A 2003-02-11 2011-10-27 多重スルファターゼ欠損症およびその他のスルファターゼ欠損症の診断および治療 Expired - Lifetime JP5527854B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44774703P 2003-02-11 2003-02-11
US60/447,747 2003-02-11

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2006503413A Division JP5241101B2 (ja) 2003-02-11 2004-02-10 多重スルファターゼ欠損症およびその他のスルファターゼ欠損症の診断および治療

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014036642A Division JP6007203B2 (ja) 2003-02-11 2014-02-27 多重スルファターゼ欠損症およびその他のスルファターゼ欠損症の診断および治療

Publications (3)

Publication Number Publication Date
JP2012090630A JP2012090630A (ja) 2012-05-17
JP2012090630A5 true JP2012090630A5 (https=) 2013-01-24
JP5527854B2 JP5527854B2 (ja) 2014-06-25

Family

ID=32869644

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2006503413A Expired - Lifetime JP5241101B2 (ja) 2003-02-11 2004-02-10 多重スルファターゼ欠損症およびその他のスルファターゼ欠損症の診断および治療
JP2011235922A Expired - Lifetime JP5527854B2 (ja) 2003-02-11 2011-10-27 多重スルファターゼ欠損症およびその他のスルファターゼ欠損症の診断および治療
JP2014036642A Expired - Lifetime JP6007203B2 (ja) 2003-02-11 2014-02-27 多重スルファターゼ欠損症およびその他のスルファターゼ欠損症の診断および治療

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2006503413A Expired - Lifetime JP5241101B2 (ja) 2003-02-11 2004-02-10 多重スルファターゼ欠損症およびその他のスルファターゼ欠損症の診断および治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014036642A Expired - Lifetime JP6007203B2 (ja) 2003-02-11 2014-02-27 多重スルファターゼ欠損症およびその他のスルファターゼ欠損症の診断および治療

Country Status (17)

Country Link
US (4) US8227212B2 (https=)
EP (3) EP2325301B1 (https=)
JP (3) JP5241101B2 (https=)
CN (4) CN1759176B (https=)
AT (1) ATE534730T1 (https=)
AU (2) AU2004210936C1 (https=)
CA (1) CA2515708A1 (https=)
CY (1) CY1117346T1 (https=)
DK (2) DK1592786T3 (https=)
ES (3) ES2566641T3 (https=)
HU (1) HUE027210T2 (https=)
MX (2) MXPA05008533A (https=)
NZ (4) NZ596420A (https=)
PT (1) PT1592786E (https=)
SI (1) SI2325302T1 (https=)
WO (1) WO2004072275A2 (https=)
ZA (1) ZA200506378B (https=)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2515708A1 (en) * 2003-02-11 2004-08-26 Transkaryotic Therapies, Inc. Diagnosis and treatment of multiple sulfatase deficiency and other sulfatase deficiencies
US8741260B2 (en) * 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
US8759297B2 (en) * 2006-08-18 2014-06-24 Armagen Technologies, Inc. Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns
US7985783B2 (en) * 2006-09-21 2011-07-26 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
AU2008282496B2 (en) 2007-07-27 2013-04-04 Armagen Technologies, Inc. Methods and compositions for increasing alpha-iduronidase activity in the CNS
MX2010003371A (es) 2007-09-28 2010-05-05 Intrexon Corp Constructos interruptores genicos terapeuticos y biorreactores para la expresion de moleculas bioterapeuticas y usos de los mismos.
CA2711590C (en) 2008-01-18 2021-03-23 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
US7722865B2 (en) 2008-01-18 2010-05-25 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
WO2009120611A2 (en) * 2008-03-27 2009-10-01 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
WO2010096394A2 (en) 2009-02-17 2010-08-26 Redwood Biosciences, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
CA2748889A1 (en) 2009-03-18 2010-09-23 Armagen Technologies, Inc. Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins
US20120301463A1 (en) 2009-09-30 2012-11-29 President And Fellows Of Harvard College Methods for Modulation of Autophagy Through the Modulation of Autophagy-Enhancing Gene Products
EP2485761B1 (en) 2009-10-09 2019-02-27 Armagen, Inc. Methods and compositions for increasing iduronate 2-sulfatase activity in the cns
US8351868B2 (en) * 2009-11-20 2013-01-08 Motorola Solutions, Inc. Radio status indicator
EP2394667A1 (en) 2010-06-10 2011-12-14 Laboratorios Del Dr. Esteve, S.A. Vectors and sequences for the treatment of diseases
AR082319A1 (es) 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
WO2012097333A2 (en) 2011-01-14 2012-07-19 Redwood Bioscience, Inc. Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
WO2012101671A1 (en) 2011-01-25 2012-08-02 Jcr Pharmaceuticals Co., Ltd. Method for production of human recombinant iduronate 2-sulfatase
US20160145589A1 (en) 2011-06-24 2016-05-26 Green Cross Corporation Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
KR101158673B1 (ko) * 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
AU2012346448B2 (en) 2011-12-02 2017-09-14 Armagen, Inc. Methods and compositions for increasing arylsulfatase A activity in the CNS
US9896715B2 (en) 2011-12-20 2018-02-20 Jcr Pharmaceuticals Co., Ltd. Method for analyzing formyl glycine residue
MX2014011836A (es) 2012-03-30 2015-03-09 Shire Human Genetic Therapies Administracion subcutanea de iduronato-2-sulfatasa.
WO2013148323A1 (en) * 2012-03-30 2013-10-03 Shire Human Genetic Therapies Methods of analyzing and preparing protein compositions
US9150841B2 (en) * 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
US20140004097A1 (en) * 2012-06-29 2014-01-02 Shire Human Genetic Therapies, Inc. Method of producing recombinant iduronate-2-sulfatase
WO2014016873A1 (en) 2012-07-26 2014-01-30 Jcr Pharmaceuticals Co., Ltd. Method for production of recombinant human alpha-galactosidase a
JP6692293B2 (ja) * 2013-07-22 2020-05-13 アーマジェン・インコーポレイテッドＡｒｍａｇｅｎ， Ｉｎｃ． Ｃｎｓにおける酵素活性を増大するための方法および組成物
EP3166626B1 (en) 2014-07-11 2021-04-28 Biostrategies LC Materials and methods for treating disorders associated with sulfatase enzymes
MA41198A (fr) 2014-12-18 2017-10-24 Shire Human Genetic Therapies Essais d'activité enzymatique pour i2s
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
WO2016116966A1 (en) 2015-01-22 2016-07-28 Jcr Pharmaceuticals Co., Ltd. Method for purification of recombinant human alpha-galactosidase a from material containing contaminant host cell proteins
JPWO2016121715A1 (ja) * 2015-01-26 2017-11-02 国立大学法人名古屋大学 肺がん患者の予後を評価するための情報を提供する方法、肺がん患者の予後予測方法、内部標準、抗体、肺がん患者の予後予測装置、予後予測装置のプログラム及び記録媒体
JP6785777B2 (ja) * 2015-02-05 2020-11-18 アール．ピー． シェーラー テクノロジーズ エルエルシー 活性化ホルミルグリシン生成酵素ならびにその生成方法及び使用方法
EP3373937B1 (en) 2015-11-09 2021-12-22 R.P. Scherer Technologies, LLC Anti-cd22 antibody-maytansine conjugates and methods of use thereof
JP2019515677A (ja) 2016-04-26 2019-06-13 アール．ピー．シェーラー テクノロジーズ エルエルシー 抗体複合体ならびにそれを作製および使用する方法
US11338046B2 (en) * 2016-09-30 2022-05-24 Esteve Pharmaceuticals, S.A. Adenoassociated virus vectors for the treatment of mucopolysaccharidoses
AU2017386888B2 (en) 2016-12-28 2024-08-08 Jcr Pharmaceuticals Co., Ltd. Lyophilized preparation
JP7303110B2 (ja) 2017-01-18 2023-07-04 ビステラ， インコーポレイテッド 抗体分子－薬物コンジュゲートおよびその使用
CR20200129A (es) 2017-10-02 2020-08-22 Denali Therapeutics Inc Proteínas de fusión que comprenden enzimas de terapia de reemplazo de enzimas
CN109628426B (zh) * 2019-01-02 2023-05-09 山东大学 一种δ4,5-己糖醛酸-2-o-硫酸酯酶及其编码基因与应用以及同类酶的鉴定方法
CN109781997A (zh) * 2019-01-22 2019-05-21 中国人民解放军总医院 用于诊断粘多糖病ⅱ型的生物标志物及其应用
KR20240085798A (ko) 2020-04-03 2024-06-17 비스테라, 인크. 항체 분자-약물 접합체 및 이의 용도
IL296986A (en) * 2020-04-06 2022-12-01 Homology Medicines Inc Adeno-associated virus preparations for ids gene transfer and methods of use thereof
CN112630430B (zh) * 2020-11-16 2021-08-27 北京美联泰科生物技术有限公司 一种定量检测uchl-1的试剂盒及其应用
CN115261495B (zh) * 2021-04-30 2024-11-22 上海旺旺食品集团有限公司 一种检测金黄色葡萄球菌的方法、检测系统及其应用
EP4346865A4 (en) 2021-05-27 2025-05-07 R.P. Scherer Technologies, LLC METHOD FOR CONTROLLING THE CLEAVAGE OF FORMYLGLYCINE-CONTAINING POLYPEPTIDES
WO2024176112A1 (en) * 2023-02-21 2024-08-29 Takeda Pharmaceutical Company Limited Large scale production of recombinant arylsulfatase a and compositions thereof
EP4704920A1 (en) * 2023-05-04 2026-03-11 Abeona Therapeutics Inc. Recombinant adeno-associated viral vectors for multipartite gene delivery and stargardt disease treatment

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US307A (en) 1837-07-29 Rqss winans
US3307A (en) 1843-10-18 Laben eddy
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US4748024A (en) 1987-04-06 1988-05-31 Endocon, Inc. Flash flow fused medicinal implants
US5674722A (en) 1987-12-11 1997-10-07 Somatix Therapy Corporation Genetic modification of endothelial cells
EP0397834B1 (en) 1988-10-28 2000-02-02 Genentech, Inc. Method for identifying active domains and amino acid residues in polypeptides and hormone variants
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5391723A (en) 1989-05-31 1995-02-21 Neorx Corporation Oligonucleotide conjugates
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB9019812D0 (en) 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
US5733761A (en) 1991-11-05 1998-03-31 Transkaryotic Therapies, Inc. Protein production and protein delivery
US6270989B1 (en) 1991-11-05 2001-08-07 Transkaryotic Therapies, Inc. Protein production and delivery
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5932211A (en) * 1991-11-12 1999-08-03 Women's And Children's Hospital Glycosylation variants of iduronate 2-sulfatase
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5645829A (en) 1993-06-18 1997-07-08 Beth Israel Hospital Association Mesothelial cell gene therapy
EP0804249A2 (en) 1994-03-15 1997-11-05 Brown University Research Foundation Polymeric gene delivery system
WO1995024920A1 (en) * 1994-03-16 1995-09-21 The Regents Of The University Of California Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor
US5863782A (en) * 1995-04-19 1999-01-26 Women's And Children's Hospital Synthetic mammalian sulphamidase and genetic sequences encoding same
US5643599A (en) 1995-06-07 1997-07-01 President And Fellows Of Harvard College Intracellular delivery of macromolecules
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
WO2001018022A1 (en) * 1999-09-03 2001-03-15 Human Genome Sciences, Inc. 52 human secreted proteins
US7368531B2 (en) * 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
EP2301947A3 (en) * 1999-02-26 2011-11-23 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof
US7083793B2 (en) * 1999-02-26 2006-08-01 Millennium Pharmaceuticals, Inc. Tango 243 polypeptides and uses thereof
JP2002017376A (ja) * 1999-07-08 2002-01-22 Herikkusu Kenkyusho:Kk 分泌蛋白質、または膜蛋白質
US6780627B1 (en) 2000-01-31 2004-08-24 Millennium Pharmaceuticals, Inc. 22438, 23553, 25278, and 26212 novel human sulfatases
AU2001238488A1 (en) * 2000-02-17 2001-08-27 Incyte Genomics, Inc. Human kinases
EP1268541A1 (en) * 2000-03-17 2003-01-02 Human Genome Sciences, Inc. 7 human ovarian and ovarian cancer associated proteins
EP2213743A1 (en) * 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Albumin fusion proteins
US20030166283A1 (en) 2000-12-21 2003-09-04 Millennium Pharmaceuticals, Inc. 22437, a novel human sulfatase and uses therefor
US20030147875A1 (en) 2000-12-27 2003-08-07 Steven Rosen Sulfatases and methods of use thereof
US20030148920A1 (en) 2000-12-27 2003-08-07 Steven Rosen Sulfatases and methods of use thereof
AU2002317700A1 (en) * 2001-06-07 2002-12-16 Hemebiotech A/S Production of recombinant human arylsulfatase a
WO2003020947A2 (en) 2001-08-31 2003-03-13 Millennium Pharmaceuticals, Inc. Mid 9002, a human sulfatase family member and uses therefor
CA2515708A1 (en) * 2003-02-11 2004-08-26 Transkaryotic Therapies, Inc. Diagnosis and treatment of multiple sulfatase deficiency and other sulfatase deficiencies
US8510225B2 (en) 2004-09-01 2013-08-13 Research In Motion Limited Split channel authenticity queries in multi-party dialog
CN105450838B (zh) 2014-09-01 2019-12-24 联想(北京)有限公司 一种信息处理方法及电子设备

Similar Documents

Publication Publication Date Title
JP2012090630A5 (https=)
Reiser et al. Potential of mesenchymal stem cells in gene therapy approaches for inherited and acquired diseases
EP2325302B1 (en) Cells that coexpress a sulfatase and a C-formylglycine generating enzyme and methods and uses thereof
US10894077B2 (en) Synthetic methylmalonyl-CoA mutase transgene for the treatment of MUT class methylmalonic acidemia (MMA)
US9944918B2 (en) Synthetic methylmalonyl-CoA mutase transgene for the treatment of MUT class methylmalonic acidemia (MMA)
US20110201673A1 (en) Lpl variant therapeutics
EP3350335A1 (en) Improved transposon system for gene delivery
WO2022051555A2 (en) Soluble alkaline phosphatase constructs and expression vectors including a polynucleotide encoding for soluble alkaline phosphatase constructs
US10696950B2 (en) Treating diabetes with genetically modified beta cells
Kucic et al. Mesenchymal stromal cells genetically engineered to overexpress IGF-I enhance cell-based gene therapy of renal failure-induced anemia
KR20150113908A (ko) 아데노바이러스 감염 및 복제가 가능한 흑색종 세포주
US20220233648A1 (en) Compositions for use in the treatment of insulin deficiency conditions
Casteilla et al. Virus-based gene transfer approaches and adipose tissue biology
US20250312382A1 (en) Cell Therapy for Treating Liver Disease
Dalberto et al. Mesenchymal stem cells as a platform for gene therapy protocols
US20030148952A1 (en) Methods and materials for the recruitment of endothelial cells
WO2015153357A1 (en) Compositions and methods for improving cardiac function
US9290751B2 (en) LPL variant therapeutics
KR20230024268A (ko) 내피 세포 및 혈관 형성을 위한 전사 인자 etv2 유전자를 사용한 직접 생체 내 재프로그래밍
Durham INBORN ERRORS OF METABOLISM-STEM CELLS AND BLOOD DISORDERS
JP2007254455A (ja) コンドロイチン硫酸合成促進剤
Zhang et al. 867. Correction of Glycogen Storage Disease Type II by Intramuscular Administration of an Adeno-Associated Virus 6 (AAV2/6) Vector Containing a Muscle-Specific Promoter
Kawabata et al. 865. An Ex Vivo Gene Therapy Approach for Metachromatic Leukodystrophy Using Neural Progenitor Cells
Schwarzwaelder et al. 33. Non-Random Genomic Distribution of Retrovirus Vector Integration in Successful SCID-X1 Gene Therapy
Mucopolysaccharidosis GENETIC AND METABOLIC DISEASES GENE & CELL THERAPY III